We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.23% | 29.75 | 29.55 | 30.50 | 30.05 | 29.53 | 29.80 | 5,444,214 | 21:57:01 |
From May 2022 to May 2024
By Stephen Nakrosis
Genentech on Thursday said the U.S. Food and Drug Administration approved a supplemental new drug application for its Xofluza to treat acute uncomplicated influenza in certain patients aged 5 to 12.
The company said Xofluza, or baloxavir marboxil, is the first single-dose oral influenza medicine approved for children in this age group.
Genentech said the FDA also approved the treatment for the prevention of influenza in children in the age group after contact with someone with influenza.
Xofluza has already been approved by the FDA to treat influenza in certain patients 12 years of age and older.
Genentech is a member of the Roche Group.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
August 11, 2022 16:15 ET (20:15 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
